Related Experiment Video
Updated: May 13, 2025
07:40
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.1K
Learning from the LEAP trial series: Optimizing clinical trial design for combination therapies
Jiatong Ding1, Yue Yu1, Dandan Cui1
1Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Med (New York, N.Y.)
|May 10, 2025
Summary
The LEAP trials showed mixed results for combining pembrolizumab and lenvatinib in cancer treatment. Further research is needed to optimize these combination therapies for better patient outcomes.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- The LEAP trial series investigated the combination of pembrolizumab and lenvatinib.
- These trials spanned multiple cancer types, evaluating synergistic effects.
Purpose of the Study:
- To analyze the outcomes of the LEAP trial series.
- To identify areas for improvement in combination cancer therapy strategies.
- To advance the development of effective therapeutic combinations.
Main Methods:
- Review of data from the LEAP trial series.
- Analysis of efficacy and safety of pembrolizumab and lenvatinib combinations.
- Identification of factors influencing treatment outcomes.
Main Results:
- The LEAP trials demonstrated varied efficacy of the pembrolizumab-lenvatinib combination across different cancers.
- Results indicate a need for deeper understanding of the synergy between these agents.
- Mixed outcomes necessitate further investigation into patient selection and treatment protocols.
Conclusions:
- The synergy of pembrolizumab and lenvatinib requires further elucidation.
- Optimizing combination strategies is crucial for improving patient outcomes in oncology.
- Future research should focus on refining combination therapy approaches based on trial learnings.
Related Concept Videos
01:11Clinical Trials: Overview
2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K
01:16Crossover Experiments
2.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.7K
01:16Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:12Hazard Ratio
69
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
69
01:28Preclinical Development: Overview
4.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.0K